Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the sale, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Joana Goncalves also recently made the following trade(s):
- On Friday, May 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $61.85, for a total value of $432,950.00.
- On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total value of $462,840.00.
Oruka Therapeutics Stock Down 1.7%
Shares of Oruka Therapeutics stock opened at $67.71 on Wednesday. The firm has a market cap of $4.08 billion, a P/E ratio of -34.90 and a beta of -0.26. Oruka Therapeutics, Inc. has a fifty-two week low of $10.77 and a fifty-two week high of $91.00. The business has a 50-day moving average price of $64.00 and a 200 day moving average price of $44.58.
Analysts Set New Price Targets
A number of brokerages have commented on ORKA. Piper Sandler restated an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Finally, Wedbush set a $165.00 target price on Oruka Therapeutics in a research note on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $131.30.
Check Out Our Latest Research Report on ORKA
Hedge Funds Weigh In On Oruka Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in ORKA. Goldman Sachs Group Inc. acquired a new position in shares of Oruka Therapeutics during the first quarter worth approximately $2,505,000. JPMorgan Chase & Co. boosted its position in shares of Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after buying an additional 13,115 shares during the period. Legal & General Group Plc acquired a new position in shares of Oruka Therapeutics during the second quarter worth approximately $28,000. Rhumbline Advisers acquired a new position in shares of Oruka Therapeutics during the second quarter worth approximately $320,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Oruka Therapeutics during the second quarter worth approximately $96,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
